Platelet-Leukocyte Interactions in Sepsis

这是修改后的NHLBI K24申请Matthew Rondina博士的职业生涯中期研究员奖-患者- 面向研究。在犹他大学，Rondina博士是资助的NHLBI R01和VA的联系人PI 优秀奖支持脓毒症患者的纵向招募以及血小板分离，临床数据 收集和结果分析。他指导着一支庞大的、不断增长的临床研究队伍，他们来自不同的 纪律。朗迪纳博士的总体目标是：1)提高他作为导师的技能，从而为更多人提供服务 有效地作为致力于以患者为中心的研究的初级调查人员的榜样和导师；2) 确定脓毒症如何上调MHCI在血小板上的抗原提呈，从而促进CD8T 细胞抑制和免疫功能障碍；以及3)从事有重点和精心选择的职业发展 增加他的T细胞生物学和免疫学知识的活动-提高他指导临床的能力 这一领域的实习生。此应用程序描述职业发展、指导和研究活动， 将在接下来的五年内根据NHLBI K24裁决提供的保护时间执行。朗迪纳医生的 学员将学习和应用创新技术来研究脓毒症患者的血小板和白细胞 适当的对照组参与者，并确定脓毒症中血小板/白细胞的变化是否与 临床结果。这个以患者为中心的研究项目将成为朗迪纳博士扩展的平台 他对学员的指导，让他们在通往成功的道路上从事以患者为导向的研究， 独立的事业。朗迪纳博士将在该项目期间从事职业发展活动， 包括1)提高他对初级临床医生调查人员的指导技能，包括代表不足的少数族裔， 2)拓展免疫学和CD8 T细胞生物学知识。这些活动将扩大Dr。 朗迪纳的指导能力、有效性和在五年获奖期内的影响力。他有足够的渠道 通过他在VPCAT和分子医学计划，犹他州斯塔尔计划， 以及犹他州CTSA KL2和TL1计划。此外，朗迪纳博士将与临床研究员在 与建议的研究相关的专科奖学金(例如，肺和危重护理、血液学、 传染病)，与犹他大学MD和MD/PhD项目的学生以及初级 调查人员来自传统上代表人数较少的背景。K24奖将使Rondina博士能够 显著扩大他的积极指导作用和以患者为导向的研究，并将导致培训 下一代生物医学科学家。

This is a revised NHLBI K24 application for Dr. Matthew Rondina’s Midcareer Investigator Award in Patient- Oriented Research. At the University of Utah, Dr. Rondina is the contact PI for a funded NHLBI R01 and VA Merit Award supporting the longitudinal recruitment of sepsis patients, as well as platelet isolation, clinical data collection, and outcomes analyses. He mentors a large and growing cadre of clinical investigators from diverse disciplines. Dr. Rondina’s overall aims are to 1) improve his skills as a mentor and therefore serve more effectively as a role model for, and mentor to, junior investigators devoted to patient-oriented research; 2) determine how sepsis upregulates antigen presentation by MHCI on platelets, thereby contributing to CD8+ T cell suppression and immune dysfunction; and 3) engage in focused and carefully selected career development activities to increase his knowledge of T cell biology and immunology – improving his ability to mentor clinical trainees in this area. This application describes career development, mentoring, and research activities that would be executed in the next five years under protected time afforded by this NHLBI K24 award. Dr. Rondina’s mentees will learn and apply innovative technologies to study platelets and leukocytes in sepsis patients and appropriate control participants, and to determine if platelet/leukocyte changes in sepsis are associated with clinical outcomes. This patient-oriented research project will serve as a platform for Dr. Rondina to expand his mentorship for trainees to engage in patient-oriented research on their path towards successful, independent careers. Dr. Rondina will engage in career development activities during this project period, including 1) improving his mentoring skills for junior clinician investigators, including underrepresented minorities, and 2) expanding his knowledge of immunology and CD8+ T cell biology. These activities will expand Dr. Rondina’s mentoring capacity, effectiveness, and reach over the five-year award period. He has ample access to mentees through his work with the VPCAT and Molecular Medicine Programs, the Utah StARR Program, and the Utah CTSA KL2 and TL1 Programs. In addition, Dr. Rondina will interface with clinical fellows in subspecialty fellowships pertinent to the research proposed (e.g. Pulmonary and Critical Care, Hematology, Infectious Disease), with students in the University of Utah MD and MD/PhD Programs, and with junior investigators from traditionally underrepresented backgrounds. The K24 award will enable Dr. Rondina to significantly expand his active mentoring roles and patient-oriented research and will lead to the training of the next-generation of biomedical scientists.